BioXcel Therapeutics (BTAI) announced a publication in the peer-reviewed journal Frontiers in Pharmacology, entitled “Dexmedetomidine potently and reversibly regulates stress-mediated behaviors.” The study demonstrated a significant effect in translatable behavioral models related to psychiatric disorders suggesting potential applications of BXCL501 in chronic conditions in addition to treatment of acute agitation. BXCL501 has already been clinically validated and FDA approved for treatment of acute episodes of agitation associated with bipolar disorder or schizophrenia. Dexmedetomidine, an alpha2-adrenergic receptor agonist, is the active ingredient in BXCL501. The published results provide further support for the drug’s mechanism of action and potential suitability for broadly addressing stress-related disorders in addition to agitation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- 3 Penny Stocks to Watch Now, 8/5/25
- Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion
- BioXcel Completes Phase 3 Trial for BXCL501
- BioXcel announces last patient visit in SERENITY at-home Phase 3 trial
- BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results